GlassScriptPhysician profile
Fify Francis Thomas
NPI 1669054953
$1,740.46
in general payments reported to CMS, 2019-2025
14 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.52 · 2024: $251 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $391.35 | 2025 | Rapiblyk |
| Astrazeneca Pharmaceuticals LP | $334.06 | 2022-2025 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $284.47 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $263.41 | 2025 | |
| Bridgebio Pharma, INC. | $128.76 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.35 | 2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.35 | 2024-2025 | Lifevest |
| Amgen INC. | $33.97 | 2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $33.35 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $30.88 | 2025 | |
| Lilly USA, LLC | $29.15 | 2022-2025 | Mounjaro |
| Ionis Pharmaceuticals, INC. | $26.45 | 2025 | |
| Esperion Therapeutics, INC. | $20.70 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $17.21 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fify Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.